**Supplemental Table 2: Glucose safety data compared across timepoints for each cohort**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Variable** | **Baseline** | **Week 5** | **Week 13** | **Baseline - Week 5 p-value** | **Baseline - Week 13 p-value** | **Week 5 - Week 13 p-value** |
| Glucose, mean (SD) |   |   |   |   |   |   |
| Cohort 1 | 63.0 (0.0) | 73.3 (20.4) | 133.0 (35.4) | 0.73 | 0.01 | 0.84 |
| Cohort 2 | 120.0 (36.4) | 65.7 (29.0) | 101.3 (11.5) | 0.01 | 0.25 | 0.42 |
| Cohort 3\* | 102.5 (14.5) | 112.6 (13.8) | 104.0 (13.9) | 0.4 | 0.98 | 0.77 |
| Reference Range | 65-99 mg/dL |   |   |   |

\*: Cohort 3 includes only the 8 patients who received >= 1 dose of eRapa and excludes the screening fail.